Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ERAP1

Gene summary for ERAP1

Gene summary.

Gene information	Species	Human
	Gene symbol	ERAP1
	Gene ID	51752
	Gene name	endoplasmic reticulum aminopeptidase 1
	Gene Alias	A-LAP
	Cytomap	5q15
	Gene Type	protein-coding
	GO ID	GO:0001525
	UniProtAcc	Q9NZ08

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
51752	ERAP1	LZE4T	Human	Esophagus	ESCC	2.70e-04	5.59e-02	0.0811
51752	ERAP1	LZE8T	Human	Esophagus	ESCC	8.81e-09	2.21e-01	0.067
51752	ERAP1	LZE24T	Human	Esophagus	ESCC	5.04e-09	1.43e-01	0.0596
51752	ERAP1	P1T-E	Human	Esophagus	ESCC	2.74e-04	1.26e-01	0.0875
51752	ERAP1	P2T-E	Human	Esophagus	ESCC	9.86e-26	5.06e-01	0.1177
51752	ERAP1	P4T-E	Human	Esophagus	ESCC	2.52e-04	8.05e-02	0.1323
51752	ERAP1	P8T-E	Human	Esophagus	ESCC	1.66e-20	1.75e-01	0.0889
51752	ERAP1	P9T-E	Human	Esophagus	ESCC	4.66e-05	5.96e-02	0.1131
51752	ERAP1	P10T-E	Human	Esophagus	ESCC	1.99e-07	-3.34e-03	0.116
51752	ERAP1	P11T-E	Human	Esophagus	ESCC	3.19e-02	1.84e-01	0.1426
51752	ERAP1	P12T-E	Human	Esophagus	ESCC	2.28e-14	1.57e-01	0.1122
51752	ERAP1	P15T-E	Human	Esophagus	ESCC	2.92e-12	2.80e-01	0.1149
51752	ERAP1	P16T-E	Human	Esophagus	ESCC	1.49e-04	-2.52e-02	0.1153
51752	ERAP1	P17T-E	Human	Esophagus	ESCC	7.60e-04	1.58e-01	0.1278
51752	ERAP1	P19T-E	Human	Esophagus	ESCC	1.45e-02	3.09e-01	0.1662
51752	ERAP1	P20T-E	Human	Esophagus	ESCC	3.49e-19	4.61e-01	0.1124
51752	ERAP1	P21T-E	Human	Esophagus	ESCC	1.69e-12	9.89e-02	0.1617
51752	ERAP1	P22T-E	Human	Esophagus	ESCC	1.60e-08	4.43e-02	0.1236
51752	ERAP1	P23T-E	Human	Esophagus	ESCC	4.04e-16	2.08e-01	0.108
51752	ERAP1	P24T-E	Human	Esophagus	ESCC	1.17e-11	1.58e-01	0.1287

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00454442	Liver	Cirrhotic	fat cell differentiation	73/4634	229/18723	8.57e-03	3.97e-02	73
GO:001988212	Liver	HCC	antigen processing and presentation	65/7958	106/18723	7.06e-05	6.37e-04	65
GO:00028312	Liver	HCC	regulation of response to biotic stimulus	173/7958	327/18723	8.55e-05	7.48e-04	173
GO:000248312	Liver	HCC	antigen processing and presentation of endogenous peptide antigen	16/7958	19/18723	2.37e-04	1.79e-03	16
GO:004800212	Liver	HCC	antigen processing and presentation of peptide antigen	40/7958	62/18723	3.84e-04	2.62e-03	40
GO:000247411	Liver	HCC	antigen processing and presentation of peptide antigen via MHC class I	21/7958	28/18723	4.94e-04	3.23e-03	21
GO:001988522	Liver	HCC	antigen processing and presentation of endogenous peptide antigen via MHC class I	14/7958	17/18723	9.39e-04	5.47e-03	14
GO:00454441	Liver	HCC	fat cell differentiation	120/7958	229/18723	1.52e-03	8.05e-03	120
GO:00065091	Liver	HCC	membrane protein ectodomain proteolysis	28/7958	43/18723	2.30e-03	1.14e-02	28
GO:003361911	Liver	HCC	membrane protein proteolysis	35/7958	57/18723	3.08e-03	1.43e-02	35
GO:00450881	Liver	HCC	regulation of innate immune response	113/7958	218/18723	3.27e-03	1.50e-02	113
GO:001988312	Liver	HCC	antigen processing and presentation of endogenous antigen	18/7958	26/18723	5.37e-03	2.24e-02	18
GO:00028317	Oral cavity	OSCC	regulation of response to biotic stimulus	177/7305	327/18723	1.73e-08	3.43e-07	177
GO:001988220	Oral cavity	OSCC	antigen processing and presentation	65/7305	106/18723	2.69e-06	3.32e-05	65
GO:00450884	Oral cavity	OSCC	regulation of innate immune response	116/7305	218/18723	1.36e-05	1.37e-04	116
GO:00454448	Oral cavity	OSCC	fat cell differentiation	120/7305	229/18723	2.48e-05	2.32e-04	120
GO:004800219	Oral cavity	OSCC	antigen processing and presentation of peptide antigen	40/7305	62/18723	4.20e-05	3.63e-04	40
GO:00336194	Oral cavity	OSCC	membrane protein proteolysis	37/7305	57/18723	6.66e-05	5.38e-04	37
GO:000247416	Oral cavity	OSCC	antigen processing and presentation of peptide antigen via MHC class I	21/7305	28/18723	1.19e-04	8.54e-04	21
GO:00065094	Oral cavity	OSCC	membrane protein ectodomain proteolysis	29/7305	43/18723	1.49e-04	1.05e-03	29

Page: 1 2 3 4 5

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ERAP1

SNV

Missense_Mutation

c.2092N>G

p.Gln698Glu

p.Q698E

Q9NZ08

protein_coding

tolerated(0.13)

benign(0.007)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ERAP1

SNV

Missense_Mutation

c.1063N>G

p.Leu355Val

p.L355V

Q9NZ08

protein_coding

deleterious(0)

probably_damaging(0.986)

TCGA-BH-A1EV-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

ERAP1

insertion

In_Frame_Ins

novel

c.1684_1685insCCGTCTCTACTAAAATACAAAAAATGAGCCGGG

p.Leu562delinsProValSerThrLysIleGlnLysMetSerArgVal

p.L562delinsPVSTKIQKMSRV

Q9NZ08

protein_coding

TCGA-A2-A0CP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

ERAP1

insertion

Nonsense_Mutation

novel

c.1544_1545insAAAAATATCCTTATAGCAAAATAGAAAATAAATTCTGACTGA

p.Val515_Asp516insLysIleSerLeuTerGlnAsnArgLysTerIleLeuThrGlu

p.V515_D516insKISL*QNRK*ILTE

Q9NZ08

protein_coding

TCGA-AN-A0FS-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

ERAP1

deletion

Frame_Shift_Del

novel

c.1199delN

p.Phe400SerfsTer11

p.F400Sfs*11

Q9NZ08

protein_coding

TCGA-D8-A27V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

ERAP1

SNV

Missense_Mutation

novel

c.2347G>T

p.Asp783Tyr

p.D783Y

Q9NZ08

protein_coding

deleterious(0)

possibly_damaging(0.849)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

ERAP1

SNV

Missense_Mutation

rs149653730

c.424G>A

p.Gly142Arg

p.G142R

Q9NZ08

protein_coding

deleterious(0)

probably_damaging(0.993)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

ERAP1

SNV

Missense_Mutation

c.2690N>G

p.Ser897Cys

p.S897C

Q9NZ08

protein_coding

deleterious(0)

probably_damaging(0.969)

TCGA-IR-A3LI-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

ERAP1

SNV

Missense_Mutation

c.1225N>A

p.Glu409Lys

p.E409K

Q9NZ08

protein_coding

tolerated(0.62)

benign(0.028)

TCGA-JX-A3Q0-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unknown

ERAP1

SNV

Missense_Mutation

novel

c.379C>A

p.Arg127Ser

p.R127S

Q9NZ08

protein_coding

tolerated(0.5)

benign(0.003)

TCGA-A6-A565-01

Colorectum

colon adenocarcinoma

Female

<65

III/IV

Unspecific

5FU

Page: 1 2 3 4 5 6 7 8 9

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
51752	ERAP1	PROTEASE, ENZYME, DRUGGABLE GENOME		TCMDC-124377	CHEMBL531269
51752	ERAP1	PROTEASE, ENZYME, DRUGGABLE GENOME	inhibitor	252166866
51752	ERAP1	PROTEASE, ENZYME, DRUGGABLE GENOME	inhibitor	CHEMBL2103847	TOSEDOSTAT
51752	ERAP1	PROTEASE, ENZYME, DRUGGABLE GENOME		UMBELLIFERONE	UMBELLIFERONE
51752	ERAP1	PROTEASE, ENZYME, DRUGGABLE GENOME		TCMDC-124673	CHEMBL587247
51752	ERAP1	PROTEASE, ENZYME, DRUGGABLE GENOME	inhibitor	348353641
51752	ERAP1	PROTEASE, ENZYME, DRUGGABLE GENOME	inhibitor	348353642
51752	ERAP1	PROTEASE, ENZYME, DRUGGABLE GENOME		SCOPOLETIN	SCOPOLETIN
51752	ERAP1	PROTEASE, ENZYME, DRUGGABLE GENOME		ESCULETIN	ESCULETIN

Page: 1